These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2468055)

  • 21. Electrophysiologic and arrhythmogenic effects of the potassium channel agonist BRL 38227 in anesthetized dogs.
    de La Coussaye JE; Eledjam JJ; Bruelle P; Peray PA; Bassoul BP; Gagnol JP; Sassine A
    J Cardiovasc Pharmacol; 1993 Nov; 22(5):722-30. PubMed ID: 7506325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the potassium channel activator, cromakalim, on arterial and cardiac responses to norepinephrine, angiotensin II, and isoproterenol in normotensive men.
    von Nguyen P; Holliwell DL; Davis A; Tasker TC; Leenen FH
    J Cardiovasc Pharmacol; 1991 Dec; 18(6):797-806. PubMed ID: 1725890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cromakalim does not protect against skeletal muscle fatigue in an anaesthetized rat model of acute hindlimb ischaemia.
    Trezise DJ; Drew GM; Roach AG; Watts IS; Weston AH
    Eur J Pharmacol; 1993 Nov; 250(1):109-16. PubMed ID: 8119308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of cromakalim, a potassium channel opener, on regional blood flow in conscious spontaneously hypertensive rats.
    Shoji T; Aki Y; Fukui K; Tamaki T; Iwao H; Abe Y
    Eur J Pharmacol; 1990 Sep; 186(1):119-23. PubMed ID: 2282933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies on the anti-vasoconstrictor activity of BRL 34915 in spontaneously hypertensive rats; a comparison with nifedipine.
    Buckingham RE
    Br J Pharmacol; 1988 Mar; 93(3):541-52. PubMed ID: 3370388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pulmonary hydraulic impedance response to cromakalim (BRL 34915) in newborn pigs.
    Domkowski PW; Cockerham JT; Kot PA; Shaffer RF; Fazzone AB; Messier RH; Wallace RB; Hopkins RA
    J Surg Res; 1994 Jun; 56(6):626-35. PubMed ID: 8015321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of ability of levcromakalim and sodium nitroprusside to reverse the cardiovascular effects of nitric oxide synthase inhibition in the anaesthetised pig.
    Herity NA; Allen JD; Silke B; Adgey AA
    Cardiovasc Res; 1994 Jun; 28(6):894-900. PubMed ID: 7522965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The antihypertensive property of NIP-121, a novel potassium channel opener in rats.
    Masuda Y; Arakawa C; Yokoyama T; Shigenobu K; Tanaka S
    J Cardiovasc Pharmacol; 1991 Aug; 18(2):190-7. PubMed ID: 1717778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of NG-nitro-L-arginine methyl ester on vasodilator responses to adrenaline or BRL 38227 in conscious rats.
    Gardiner SM; Kemp PA; Bennett T
    Br J Pharmacol; 1991 Nov; 104(3):731-7. PubMed ID: 1797333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regional hemodynamic dose-response of lemakalim and glybenclamide in anesthetized rats.
    Smits GJ; Perrone MH; Cox BF
    J Cardiovasc Pharmacol; 1997 Jan; 29(1):49-56. PubMed ID: 9007670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potassium channel opening drug cromakalim produces arterioselective vasodilation in the upper limbs of healthy volunteers.
    Webb DJ; Benjamin N; Vallance P
    Br J Clin Pharmacol; 1989 Jun; 27(6):757-61. PubMed ID: 2757892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of cromakalim on skeletal muscle function and blood flow in the ferret ischemic hindlimb.
    Weselcouch EO; Baird AJ
    Pharmacology; 1994 Aug; 49(2):75-85. PubMed ID: 7972324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the K+ channel activators, RP 52891, cromakalim and diazoxide, on the plasma insulin level, plasma renin activity and blood pressure in rats.
    Pratz J; Mondot S; Montier F; Cavero I
    J Pharmacol Exp Ther; 1991 Jul; 258(1):216-22. PubMed ID: 1906538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerance to cromakalim in the rat uterus in vivo.
    Downing SJ; Miller M; Hollingsworth M
    Br J Pharmacol; 1989 Mar; 96(3):732-8. PubMed ID: 2720301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical studies with the potassium channel activator cromakalim in normotensive and hypertensive subjects.
    Donnelly R; Elliott HL; Meredith PA; Reid JL
    J Cardiovasc Pharmacol; 1990 Nov; 16(5):790-5. PubMed ID: 1703602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of cromakalim on kidney function in the anaesthetised rat.
    Johns EJ; Marriott I
    Br J Pharmacol; 1989 Dec; 98 Suppl():821P. PubMed ID: 2611527
    [No Abstract]   [Full Text] [Related]  

  • 37. Vasorelaxant effects of cromakalim in rats are mediated by glibenclamide-sensitive potassium channels.
    Cavero I; Mondot S; Mestre M
    J Pharmacol Exp Ther; 1989 Mar; 248(3):1261-8. PubMed ID: 2495353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cromakalim and cicletanine against pacing-induced myocardial ischemia in conscious rabbits.
    Szilvassy Z; Koltai M; Ferdinandy P; Jakab I; Lonovics J; Tarrade T; Allard M; Braquet PG
    Life Sci; 1994; 54(9):PL125-30. PubMed ID: 8114606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of cromakalim on micturition function in rats.
    Smith AB; Bertelsen DL; Kau ST; Chun AL
    Neurourol Urodyn; 1993; 12(1):99-108. PubMed ID: 8481733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined administration of an IK(ATP) activator and Ito blocker increases coronary flow independently of effects on heart rate, QT interval, and ischaemia-induced ventricular fibrillation in rats.
    Rees SA; Tsuchihashi K; Hearse DJ; Curtis MJ
    J Cardiovasc Pharmacol; 1993 Sep; 22(3):343-9. PubMed ID: 7504122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.